Key benefits of the Randox sdLDL-C assay
Randox sdLDL-C utilises the “Denka Seiken” method
The “Denka Seiken” method produces results in as little as ten minutes, facilitating faster patient diagnosis and treatment plan implementation. The previous methods, ultracentrifugation and electrophoresis, were laborious and time consuming.
Exceptional correlation with the gold standard method
A correlation coefficient of r=0.99 was displayed when the Randox methodology was compared against the gold standard method, ultracentrifugation.
Wide measuring range
The healthy upper limit for sdLDL-C 4.90mmol/l. The Randox sdLDL-C assay can comfortably detect levels outside of the healthy range, measuring between 4 – 100mg/dl.
Liquid ready-to-use assay
The Randox sdLDL-C assay is available in a liquid ready-to-use format for convenience and ease-of-use.
Stable to expiry date
The Randox sdLDL-C assay is stable to expiry date when stored at +2 to +8°C
Applications are available
Applications are available detailing instrument-specific settings for the convenient use of the Randox sdLDL-C assay on a wide range of clinical chemistry analysers. Contact us to enquire about your specific analyser.
|(U) Indicates for use in the USA only
(*) Indicates that boths kits must be purchased together
|562616||R1 1 x 19.8ml|
R2 1 x 8.6ml
|CH8153||R1 1 x 16.2ml|
R2 1 x 8.2ml
|562760 (U)||R1 1 x 18ml|
R2 1 x 7ml
|562791 *(U)||R1 5 x 200ml||General Use||-||-|
|562807 *(U)||R2 2 x 200ml||General Use||-||-|
When measuring LDL cholesterol (LDL-C), it is the cholesterol mass within the LDL particles that is being measured. The LDL particle population within LDL is heterogeneous – meaning that the size, density & composition of each particle will be different. sdLDL-C is a subfraction of low density lipoprotein (LDL) with smaller particle size and higher density than larger more buoyant LDL. They all transport triglycerides and cholesterol to the tissues, but their atherogenesis varies according to their size. sdLDL-C will more readily permeate the inner arterial wall. sdLDL-C is more susceptible to oxidation and has a lower affinity to the hepatic LDL receptor, and as such circulates in the blood longer1.
As sdLDL-C is particularly atherogenic, a person with elevated sdLDL-C levels has a 3-fold increased risk of myocardial infarction (MI)2.
sdLDL-C measurement therefore provides a more comprehensive understanding of cardiovascular disease (CVD) risk compared to traditional LDL-C tests.
Reducing sdLDL-C levels will aid in reducing the risk of CVD and MI. High dose statin therapy has been proven to aid in reducing the levels of sdLDL-C as a risk factor for cardiovascular events and high risk patients. Elevated levels of sdLDL-C arise from multiple sources. A major factor is a sedentary lifestyle with a diet high in saturated fat. Insulin resistance and pre-diabetes have also been implicated, in addition to genetic predisposition3.
The measurement of LDL-C or the review of levels within arteriosclerotic coronary heart disease (ASCHD) treatment are known within different guidelines (including ATP III, AHA/ ACC, ESC/ EAS and NICE). However doubt remains on the impact of targeting LDL-C only. The inclusion of sdLDL-C within the clinical testing panel will assist in removing this doubt.
The only direct automated sdLDL-C kit on the market, the Randox sdLDL-C ‘Ex-Seiken’ test is a direct method for the quantitative determination of sdLDL-C using automated chemistry analysers capable of accommodating two-reagent assays. The assay consists of two steps and is based on the use of well-characterised surfactants and enzymes that selectively react with certain groups of lipoproteins.
Want to know more?
Contact us or visit the Randox Lipid Testing Panel page to learn more.
Lipid EQA Scheme
1. Hirano. T, et al, 2005, “Measurement of small dense low-density lipoprotein particles”. J Atheroscler Thromb, 12, 67
2. Austin. MA, et at, “Low-density lipoprotein subclass patterns and risk of MI”. JAMA 260, 1917, 1988
3. Najmafshar, A.wt al, 2012. “The Correlation between Overweight and Obesity with Plasma Levels of leptin, Insulin and sdLDL in People over 20 Years Old”. Journal of Obesity & Weight Loss Therapy. 2 (8), 1-3